The role of prognostic and predictive markers in cancer

Cancer Forum

Volumn 32, Issue 3, 2008, Pages 139-142

  Lord, Sarah ^a   Lee, Chee ^a   Simes, R John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; K RAS PROTEIN; MOLECULAR MARKER; PANITUMUMAB; PROTEIN P53; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL DECISION MAKING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; NEOPLASM; PREDICTION; PROGNOSIS; RISK REDUCTION; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 57049142221     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 69(3):89-95, 2001.
2. Ransohof DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol. 2007.
3. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 88(20):1456-66, 1996.
4. Hayes DF. Assessing the clinical impact of prognostic factors; when is 'statistically significant' clinically useful? Breast Cancer Res Treat. 100(2):229-35, 1998; 52:305-319.
5. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365(9472):1687-717, 2005;-20.
6. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 159(9):882-90, 2004.
7. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nature Clinical Practice Oncology 3(10):540-51, 2006.
8. Buyse M, Loi S, van't VL, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 98(17):1183-92, 2006.
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235(4785):177-82, 1987.
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707-12, 1989.
11. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344(11):783-92, 2001.
12. Van CE, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 25(13):1658-64, 2007.
13. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2008, 26(10):1626-1634.
14. Van CE, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 25(13):1658-64, 2007.
15. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2008; 26(10):1626-1634.
16. Kandioler D, Jakesz R. p53 as a prognostic and predictive indicator. In: Gasparini G, Hayes DF, editors. Biomarkers in breast cancer - Molecular diagnostics for predicting and monitoring therapeutic effect. Totowa, NJ: Humana Press; 2006. 193-209.